Articles tagged with Medications
Access to buprenorphine and naltrexone for opioid use disorder is affected by race and ethnicity, as well as insurance type. Targeted interventions, including culturally tailored care and expanded access points, are needed to address disparities and reduce inequities contributing to the overdose crisis.
Most opioid treatment programs still do not offer all three forms of medication-assisted treatment (MAT) as of 2023. Government-operated programs and those accepting Medicare are more likely to provide comprehensive MAT offerings.
A new gene therapy delivery device called NANOSPRESSO could revolutionize how hospitals treat rare diseases by allowing them to create personalized nanomedicines in-house. This democratized approach to precision medicine could boost access to low-cost bespoke gene and RNA therapies, especially in low-resource settings.
Research found that ADHD medication was associated with lower risks of self-harm, unintentional injury, and crime, but the magnitude of these associations decreased as prescription rates rose. The study highlights the need to regularly assess medication use in different patient populations.
A new online toolkit developed by the University of Ottawa and Health Canada aims to educate healthcare providers on managing opioid-related issues. The toolkit's co-creation model involves patient input, leading to a deeper understanding of chronic pain and opioid use, and a more compassionate approach to care.
Scientists at Xi'an Jiaotong-Liverpool University developed a new nanoparticle capable of carrying high doses of chemotherapy drugs while staying stable for extended periods. This innovation could make treatments more effective and reduce side effects.
A cross-sectional study of 23,000 adolescents found significant racial and ethnic disparities in mental health service use among minority groups. Adolescents from minority groups were less likely to receive mental health visits or psychotropic medications, underscoring the importance of improving access for these populations.
The National Urea Cycle Disorders Foundation is establishing a multistakeholder Partner Network to guide health care decisions and build a sustainable infrastructure for UCD research. The project aims to empower the broad UCD community to work together effectively, identify research needs, and create a roadmap for future studies.
A new study reveals that Rapamycin has a comparable life-extending effect to dietary restriction in eight species of vertebrates. The compound, originally developed as an immunosuppressant, offers similar benefits without the need for caloric restriction.
Researchers from Florida Atlantic University's Charles E. Schmidt College of Medicine aim to reduce falls and adverse drug events among older adults by using personalized approach tailored to individual genetic profiles.
Researchers discover iguratimod, a rheumatoid arthritis drug, effectively treats excessive COVID-19 inflammation in mice by maintaining antiviral immune responses. The study provides hope for patients with severe COVID-19-related cytokine storms.
A new study found that taking antipsychotic medication as prescribed significantly reduces the odds of a motor vehicle crash among drivers with schizophrenia. Researchers analyzed 20 years of data and found a 50% reduction in crash risk among those who adhered to their medication.
Researchers review nanozymes derived from Chinese herbs, including their catalytic properties, biomedical applications, and potential challenges in developing herbzymes for practical use. The review highlights three main types of herbzymes: herb carbon dot enzymes, polyphenol-metal nanozymes, and herb extract nanozymes.
High blood pressure typically has no signs or symptoms, according to the CDC. Few U.S. adults can correctly identify what blood pressure reading is considered high (130/80 mmHg). Despite prevalence, many people mistakenly believe high blood pressure always has noticeable symptoms or can be identified by feeling calm and relaxed.
A new USC-led study finds that a focused intervention combining storytelling, peer support, and provider incentives can reduce provider bias in family planning clinics and improve care for young women. The intervention expanded contraceptive access for the most marginalized groups.
The American Society for Nutrition released a clinical advisory outlining eight key nutritional priorities to support GLP-1 therapy, including personalized diets, micronutrient prevention, and adequate protein intake. Studies have shown that patients receiving combined pharmacologic and lifestyle interventions achieve greater weight lo...
A Virginia Tech professor has received a proof-of-concept grant to further develop a chemical compound that could help promote weight loss by increasing mitochondrial activity. The compound, named BAM15, shows promise in preclinical studies without affecting food intake or muscle mass.
Acupuncture was found to be an effective treatment for nocturia in survivors of prostate cancer, reducing symptoms comparable to other medications while causing fewer side effects. The study suggests acupuncture may offer a new hope for managing this common issue affecting half of prostate cancer survivors.
A qualitative study found that patients' attitudes towards deprescribing are shaped by their perception of medication's benefits and risks, as well as their level of autonomy. Patients who valued negative aspects of medication and had a proactive approach to health were more likely to consider cutting back on prescriptions.
Sustained midlife weight loss was associated with lower chronic disease incidence and decreased all-cause mortality. The study's findings suggest that maintaining a healthy weight during middle age can have long-term health benefits.
A new study finds that cannabis use disorder diagnoses rose substantially across all age groups, race/ethnicity, and comorbidity subgroups nationwide from 2000 to 2022. People living with HIV experienced the greatest relative increase in CUD diagnoses, particularly among older adults.
A new study found that people taking antidepressants for over two years are more likely to experience withdrawal symptoms, including anxiety and fatigue. Long-term users also tend to have worse withdrawal symptoms and are less able to stop taking the medication.
A new framework for assessing traumatic brain injuries (TBI) will provide more accurate diagnoses and treatments, leading to better patient outcomes. The framework incorporates clinical symptoms, biomarkers, imaging scans, and modifiers to determine the severity of injury and predict recovery.
Researchers found methotrexate to be non-inferior to prednisone in controlling pulmonary sarcoidosis after 24 weeks of treatment, but had a slower onset of efficacy. The study suggests an alternative first-line treatment for patients with pulmonary sarcoidosis who want to avoid steroid side effects.
Research reveals individuals taking oral steroids for over 3 months are 6 times more likely to be diagnosed with adrenal insufficiency than those treated with non-steroidal anti-inflammatory drugs. Long-term users of inhaled steroids also face increased risk without hospitalisations.
Research suggests that antibiotics taken during infancy, especially in the first three months, may lead to earlier onset of puberty in girls. The study, which analyzed data on over 322,000 children in South Korea, found a significant association between early antibiotic exposure and increased risk of central precocious puberty.
A new study found that only 39% of clinical trials report the race or ethnicity of participants involved. The research highlights the need for more comprehensive reporting and recruitment practices to ensure studies better reflect diverse populations globally. This is crucial for developing inclusive, effective, and equitable treatments.
A new study suggests that European member states must work together and provide better incentives to develop new medicines. The research highlights the need for faster approval times and stronger support for innovative drugs to attract leading pharmaceutical companies.
A new study at Columbia University Mailman School of Public Health found an increase in use of only psychotherapy, from 11.5% to 15.4%, and a decline in patients taking medication only, from 68% to 62%. The shift may be attributed to various factors beyond the COVID pandemic.
Despite slight increase in prescriptions between 2021 and 2024, only 3% of eligible patients received a prescription. Disparities were found based on race, ethnicity, social vulnerability, and urbanicity, with small but significant differences compared to overall underutilization.
A cohort study of pregnant individuals with opioid use disorder found that buprenorphine treatment was associated with improved maternal and infant outcomes. The study highlights the need to improve access to treatment nationwide for these patients.
A 12-week randomized clinical trial shows varenicline combined with behavioral counseling effectively increased vaping abstinence in youth who vape nicotine but do not regularly smoke tobacco. This study provides hope for a novel treatment approach to help combat the growing youth vaping epidemic.
A recent study has made a breakthrough in understanding the genetic underpinnings of osteoarthritis by identifying 962 genetic markers associated with the condition. The researchers found 513 new genetic markers that were not previously reported, providing potential new drug targets and opportunities for repurposing existing medications.
A new class of antibiotic has been shown to be effective in treating MRSA infections, with a daily dose of epidermicin NI01 demonstrating equal efficacy to the current standard of care. The findings justify further pre-clinical development and could lead to new gel-type therapies for skin infections.
A study found that New York's opioid restriction law led to decreased opioid quantities after total joint replacement surgeries. The findings suggest refining laws may further reduce opioid prescribing nationwide.
Research reveals that GLP-1RAs and SGLT2i medications significantly reduce the risk of Alzheimer's disease and related dementias in people with type 2 diabetes. No significant difference was found between these two treatments.
The Finerenone Trial found that sudden death was the primary cause of higher cardiovascular mortality in patients with heart failure and mild or preserved ejection fractions. The study suggests that finerenone may not significantly impact cardiovascular mortality, but its effects on overall mortality are unclear.
A study published in JAMA Cardiology found that finerenone was effective in treating heart failure, regardless of the presence of atrial fibrillation. New-onset atrial fibrillation was linked to a substantially increased risk of adverse outcomes.
A cohort study found semaglutide use is associated with a higher risk of nonarteritic anterior ischemic optic neuropathy in people with diabetes. However, the retrospective design limits the study's ability to establish causality, necessitating further research.
Most older U.S. adults support Medicare covering weight management medications, particularly those with a BMI of 30 or greater. The survey also found that more than half of participants were interested in using these medications to manage their weight.
A new study found that exercise significantly reduced falls among elderly women with polypharmacy. Those using multiple medications benefited the most from the intervention, experiencing a 29% lower risk of fall compared to the control group.
A new survey found that patients with neurological and mental health disorders prefer non-invasive neuromodulation interventions over current medications. The study, published in Scientific Reports, suggests that providing accurate information to patients improves their perception of these treatments.
The study found that the prevalence of adults with diabetes did not significantly change between 2013 and 2023. However, glycemic control among those with diagnosed disease worsened, particularly among young adults. This trend is concerning due to its potential impact on lifetime risk of cardiovascular events.
Researchers have discovered that commonly prescribed medications can disrupt sterol biosynthesis in developing brains, potentially affecting neural development and function. The study highlights the need for reevaluating medication safety during pregnancy and early childhood.
A cohort study found that patients with obesity undergoing joint replacement who experienced significant weight loss after initiating anti-obesity medications had a lower risk of 5-year and 10-year revision. This suggests that safe and sustainable weight loss may improve implant survivorship in obese patients.
A study published in JAMA Ophthalmology found a modest increase in the risk of nonarteritic anterior ischemic optic neuropathy among individuals with type 2 diabetes associated with semaglutide use. The findings suggest that further investigation is needed into the clinical implications of this association.
A new study found that generic drugs made in India have significantly more 'severe adverse events' for patients, including hospitalization and death. The researchers matched 2,443 drugs made in the US and emerging economies, finding that mature generic drugs were responsible for the higher rates of severe adverse events.
A study by University of Bath researchers found that stopping anticoagulants for patients aged 75 and over does not significantly affect the risk of major bleeding, but increases the risk of serious events like stroke and death. This highlights the need for clinicians to carefully consider the risks of stopping anticoagulation therapy ...
The study found a significant increase in obesity drug prescriptions from 0.76 million in July 2017 to 1.5 million in February 2024, mirroring rising public online search activity for semaglutide and tirzepatide. This correlation highlights the real-time association between public awareness and prescription trends.
A cohort study found that insurance plan type and structure play a crucial role in determining access to semaglutide for adults with obesity. The findings suggest that targeted interventions at the insurance level could improve equity in obesity treatment access.
A polypill containing a statin and three half-standard dose antihypertensives could significantly reduce health disparities in low-income, majority Black populations with limited access to healthcare. The study suggests that this treatment approach may be a high-value intervention for preventing cardiovascular disease.
A cross-sectional study found that maternal use of certain antidepressants and anti-inflammatory medications can lower protein and fat levels in breast milk. This may impose health risks on infants who are breastfed by mothers taking these medications, highlighting the need for further research to clarify the clinical implications.
A recent study found that approximately 1 in 3 U.S. retail pharmacies have closed since 2010, primarily driven by chain pharmacy closures and industry consolidation. This decline significantly impacts public health, making it harder for people to access prescriptions and essential health services.
A cohort study found that nearly half of participants who consumed alcohol at baseline decreased their alcohol use after initiating anti-obesity medication treatment. The medications, such as naltrexone and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), may have properties that lead to reduced cravings for alcohol.
A study estimates that approximately one-third of eligible US adults without diabetes were excluded from clinical trials supporting GLP-1 and GLP-1/GIP medications. The FDA should consider updating labeling to advise caution on generalizing these medications' safety and effectiveness to excluded populations.
A study of U.S. adults on anti-obesity medications found that 25% reported wasting more food since taking the drugs, while changes in diet and eating habits appeared to offset some of this waste, particularly among those who consumed more vegetables.
A study reveals that nearly 137 million US adults are eligible for semaglutide therapy, more than the number eligible for statins. Semaglutide's broad eligibility could lead to increased adoption and treatment options for US adults.
Researchers found semaglutide and liraglutide substantially decrease AUD hospitalization risk compared to approved medications. Clinical trials are needed to confirm these findings and explore their efficacy in treating AUD.
A study published in JAMA found that drug-related reports of supply chain issues were 40% less likely to result in meaningful drug shortages in Canada compared to the US. This highlights the importance of global cooperation to curb the effects of drug shortages and strengthen pharmaceutical supply chains.
A new study published in JAMA found that reports of drug supply-chain issues were 40% less likely to result in drug shortages in Canada compared to the US. The analysis looked at drugs with reports of supply-chain disruptions between 2017 and 2021 in both countries, and found nearly half resulted in shortages in the US within 12 months.